
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JATENZO [®] safe effectively. See full prescribing information for JATENZO. JATENZO (testosterone undecanoate) capsules, for oral use CIII Initial U.S. Approval: 1953	-
Boxed Warning, Increases in Blood Pressure	Removed
03/2025	hemoved
Indications and Usage (1) 03/2025	
Contraindications, Men with "age related hypogonadism" (4) 03/2025	Removed
Warnings and Precautions, Venous Thromboembolism (5.2) 03/2025	
Warnings and Precautions, Blood Pressure Increases (5.4) 03/2025	
Warnings and Precautions, Cardiovascular Risk (5.3) 03/2025	Removed
INDICATIONS AND USAGE	
JATENZO (testosterone undecanoate) is an androgen indicated for testosterone replacement adult males for conditions associated with a deficiency or absence of endogenous testosteron Limitations of use:	therapy in e (1).
 Safety and efficacy of JATENZO in men with "age-related hypogonadism" have not been es Safety and efficacy of JATENZO in males less than 18 years old have not been established 	
DOSAGE AND ADMINISTRATION	
 Prior to initiating JATENZO, confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate that these concentrations are below the normal range (2.1). Take JATENZO with food (2.2). Starting dose: 237 mg orally once in the morning and once in the evening. Adjust the dose to a minimum of 158 mg twice daily and a maximum of 396 mg twice daily serum testosterone drawn 6 hours after the morning dose at least 7 days after starting tree following dose adjustment and periodically thereafter (2.2). 	days and based on
DOSAGE FORMS AND STRENGTHS	
JATENZO (testosterone undecanoate) capsules for oral use are available in the following stren mg, 198 mg, 237 mg (3).	gths: 158
CONTRAINDICATIONS	
 Men with breast cancer or known or suspected prostate cancer (4, 5.3). Women who are pregnant. Testosterone may cause fetal harm (4, 5.6, 8.1, 8.2). Known hypersensitivity to JATENZO or any of its ingredients (4). 	
WARNINGS AND PRECAUTIONS	
 Polycythemia: Monitor hematocrit approximately every 3 months to detect increased red b mass and polycythemia (5.1). 	lood cell
 Venous thromboembolism (VTE): VTE, including deep vein thrombosis (DVT) and pulmonar (PE), have been reported in patients using testosterone. Evaluate patients with signs or syn consistent with DVT or PE (5.2). 	
 Worsening of Benign Prostatic Hyperplasia (BPH) and Potential Risk of Prostate Cancer: Mo with benign prostatic hyperplasia (BPH) for worsening of signs and symptoms of BPH (5.3). Blood Pressure Increases: JATENZO can increase blood pressure, which can increase cardio 	
over time. Measure blood pressure periodically. Not recommended for use in men with unc hypertension (5.4)	ontrolled
 Abuse of Testosterone: Testosterone has been subject to abuse, typically at doses higher t recommended for the approved indication and in combination with other anabolic androger (5.5). 	
 Potential for Adverse Effects on Spermatogenesis: Exogenous administration of androgens azoospermia (5.7). 	-
• Edema: Edema, with or without congestive heart failure, may occur in patients with pre-exist renal, or hepatic disease (5.9, 6.1).	sting cardiac,
 Sleep Apnea: Sleep apnea may occur in those with risk factors (5.11). Monitor prostate specific antigen (PSA) and lipid concentrations periodically (5.3, 5.12). Risk of Depression and Suicide: Depression and suicidal ideation have occurred during clinic patients treated with JATENZO (5.15). 	cal trials in

Most common adverse reactions (incidence > 2%): polycythemia, diarrhea, dyspepsia, eructation,

peripheral edema, nausea, increased hematocrit, headache, prostatomegaly, and hypertension (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Tolmar, Inc. at 1-844-4TO-LMAR or FDA at 1-800-FDA-1088 or <u>www.fda.gov/medwatch</u>.

-----DRUG INTERACTIONS

- Androgens may decrease blood glucose and therefore may decrease insulin requirements in diabetic patients (7.1).
- Changes in anticoagulant activity may be seen with androgens. More frequent monitoring of International Normalized Ratio (INR) and prothrombin time is recommended in patients taking warfarin (7.2).
- Use of testosterone with corticosteroids may result in increased fluid retention. Use with caution, particularly in patients with cardiac, renal, or hepatic disease (7.3).
- Concomitant administration of medications that are known to increase blood pressure may lead to additional increases in blood pressure when used with JATENZO (7.4).
- USE IN SPECIFIC POPULATIONS
- Geriatric Patients: There are insufficient long-term safety data to assess the potential risks of cardiovascular disease and prostate cancer (8.5).

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 3/2025

FULL PRESCRIBING INFORMATION: CONTENTS* RECENT MAJOR CHANGES 1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

- 2.1 Confirmation of Hypogonadism Before Initiation of JATENZO
- 2.2 Dosing and Dose Adjustment Information

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Polycythemia
- 5.2 Venous Thromboembolism

5.3 Worsening of Benign Prostatic Hyperplasia (BPH) and Potential Risk of Prostate Cancer

- 5.4 Blood Pressure Increases
- 5.5 Abuse of Testosterone and Monitoring of Testosterone Concentrations
- 5.6 Not for Use in Women
- 5.7 Potential for Adverse Effects on Spermatogenesis
- 5.8 Hepatic Adverse Effects
- 5.9 Edema
- 5.10 Gynecomastia
- 5.11 Sleep Apnea
- 5.12 Lipid Changes
- 5.13 Hypercalcemia
- 5.14 Decreased Thyroxine-binding Globulin
- 5.15 Risk of Depression and Suicide

6 ADVERSE REACTIONS

- 6.1 Clinical Trial Experience
- 6.2 Postmarketing Experience

7 DRUG INTERACTIONS

- 7.1 Insulin
- 7.2 Oral Vitamin K Antagonist Anticoagulants
- 7.3 Corticosteroids
- 7.4 Medications that May Also Increase Blood Pressure

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential
- 8.4 Pediatric Use
- 8.5 Geriatric Use

9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

- 9.2 Abuse
- 9.3 Dependence
- **10 OVERDOSAGE**

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES

- 14.1 Clinical Trials in Hypogonadal Males
- **16 HOW SUPPLIED/STORAGE AND HANDLING**

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

JATENZO (testosterone undecanoate) is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone:

- Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
- Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from causes such as tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range.

Limitations of use:

- Safety and efficacy of JATENZO in men with "age-related hypogonadism" have not been established.
- Safety and efficacy of JATENZO in males less than 18 years old have not been established [see Use in Specific Populations (8.4)].

2 DOSAGE AND ADMINISTRATION

2.1 Confirmation of Hypogonadism Before Initiation of JATENZO

Prior to initiating JATENZO, confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these testosterone concentrations are below the normal range.

2.2 Dosing and Dose Adjustment Information

Individualize the dosage of JATENZO based on the patient's serum testosterone concentration response to the drug. The recommended starting dose is 237 mg taken orally twice daily, once in the morning and once in the evening. Take JATENZO with food.

<u>Dose Adjustment</u>

To ensure proper dose adjustment, measure serum testosterone concentrations 6 hours after the morning dose in plain tubes, clotted at room temperature for 30 minutes prior to centrifugation. Adjust the JATENZO dose based on this serum testosterone measurement as shown in Table 1. Wait seven days after starting treatment or adjusting the dose before checking the serum testosterone concentration. Thereafter, periodically monitor serum testosterone concentrations 6 hours after the morning dose.

Administer the same dose in the morning and evening. The minimum recommended dose is 158 mg twice daily. The maximum recommended dose is 396 mg (two 198 mg capsules) twice daily.

Testosterone Concentration in Serum From Plain Tube Drawn 6 hours After Morning Dose	Current JATENZO Dose (mg, twice daily)	New JATENZO Dose (mg, twice daily)
	158	198
Loss than 125 ng/dl	198	237
Less than 425 ng/dL	237	316 (two 158 mg capsules)
	316 (two 158 mg capsules)	396 (two 198 mg capsules)
425 ng/dL – 970 ng/dL	No Dose Change	
	396 (two 198 mg capsules)	316 (two 158 mg capsules)
	316 (two 158 mg capsules)	237
More than 970 ng/dL	237	198
	198	158
	158	Discontinue Treatment

Table 1: JAT	ENZO Dose	Adjustment	Scheme
--------------	-----------	------------	--------

3 DOSAGE FORMS AND STRENGTHS

JATENZO capsules for oral use are available in three strengths:

- The 158 mg testosterone undecanoate capsules are opaque red and imprinted with "158" in white ink.
- The 198 mg testosterone undecanoate capsules are opaque white and imprinted with "198" in red ink.
- The 237 mg testosterone undecanoate capsules are opaque orange and imprinted with "237" in white ink.

4 CONTRAINDICATIONS

JATENZO is contraindicated in:

- Men with carcinoma of the breast or known or suspected carcinoma of the prostate [see Warnings and Precautions (5.3)].
- Women who are pregnant. Testosterone can cause virilization of the female fetus when administered to a pregnant woman [see Use in Specific Populations (8.1)].
- Men with known hypersensitivity to JATENZO or any of its ingredients [*see Description (11)*].

5 WARNINGS AND PRECAUTIONS

5.1 Polycythemia

Increases in hematocrit reflective of increases in red blood cell mass, may require lowering the dose or discontinuation of JATENZO. Check that hematocrit is not elevated prior to initiating JATENZO. Evaluate hematocrit approximately every 3 months while the patient is on JATENZO. If hematocrit becomes elevated, stop JATENZO until the hematocrit decreases to an acceptable concentration. If JATENZO is restarted and again causes hematocrit to become elevated, stop JATENZO permanently. An increase in red blood cell mass may increase the risk of thromboembolic events [*see Warnings and Precautions (5.2*)].

5.2 Venous Thromboembolism

There have been postmarketing reports of venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients using testosterone replacement products such as JATENZO.

In the Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study, a randomized, doubleblind, placebo-controlled, cardiovascular (CV) outcomes study, compared to placebo, topical testosterone gel was associated with a higher risk of VTE (1.7% vs 1.2%) which included DVT (0.6% vs 0.5%) and PE (0.9% vs 0.5%) [see Adverse Reactions (6.1)].

Evaluate patients who report symptoms of pain, edema, warmth and erythema in the lower extremity for DVT and those who present with acute shortness of breath for PE. If a venous thromboembolic event is suspected, discontinue treatment with JATENZO and initiate appropriate workup and management [*see Adverse Reactions (6.2)*].

5.3 Worsening of Benign Prostatic Hyperplasia (BPH) and Potential Risk of Prostate Cancer

Patients with BPH treated with androgens are at an increased risk for worsening of signs and symptoms of BPH. Monitor patients with BPH for worsening signs and symptoms.

Patients treated with androgens may be at increased risk for prostate cancer. Evaluate patients for prostate cancer prior to initiating and during treatment with androgens [see *Contraindications (4)*].

5.4 Blood Pressure Increases

JATENZO can increase blood pressure. Ambulatory blood pressure monitoring (ABPM) demonstrated JATENZO increased systolic /diastolic BP by an average of 4.9/2.5 mmHg from baseline after 4 months of treatment in a clinical trial [see Adverse Reactions (6.1)]. In patients with hypertension on antihypertensive therapy, JATENZO increased the mean systolic/diastolic BP by 5.4/3.2 mmHg from baseline. Average blood pressures had not plateaued at the end of the trial.

The CV risk associated with topical testosterone gel was evaluated in TRAVERSE, a randomized, double-blind, placebo-controlled, CV outcomes study in men with a history of CV disease or multiple CV risk factors. In TRAVERSE, topical testosterone gel increased mean systolic blood pressure by 1.8 mmHg from baseline. However, the incidences of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction [MI] and non-fatal stroke, were similar between treatment groups (7% for topical testosterone gel vs 7.3% for placebo) [See Adverse Reactions (6.1)].

Monitor blood pressure periodically in men using JATENZO, especially men with hypertension. JATENZO is not recommended for use in patients with uncontrolled hypertension.

5.5 Abuse of Testosterone and Monitoring of Testosterone Concentrations

Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids. Anabolic androgenic steroid abuse can lead to serious cardiovascular and psychiatric adverse reactions [*see Drug Abuse and Dependence (9)*].

If testosterone abuse is suspected, check testosterone concentrations to ensure they are within therapeutic range [see *Dose and Administration (2)*]. However, testosterone levels may be in the normal or subnormal range in men abusing synthetic testosterone derivatives. Counsel patients concerning the serious adverse reactions associated with abuse of testosterone and anabolic androgenic steroids. Conversely, consider the possibility of testosterone and anabolic androgenic steroid abuse in suspected patients who present with serious cardiovascular or psychiatric adverse events.

5.6 Not for Use in Women

Due to lack of controlled studies in women and potential virilizing effects, JATENZO is not indicated for use in women [*see Contraindications (4)* and *Use in Specific Populations (8.1, 8.2)*].

5.7 Potential for Adverse Effects on Spermatogenesis

With large doses of exogenous androgens, including JATENZO, spermatogenesis may be suppressed through feedback inhibition of pituitary FSH possibly leading to adverse effects on semen parameters including sperm count [*see Use in Specific Populations* (8.3)]. Patients should be informed of this possible risk when deciding whether to use or to continue to use JATENZO.

5.8 Hepatic Adverse Effects

Prolonged use of high doses of orally active 17-alpha-alkyl androgens (e.g., methyltestosterone) has been associated with serious hepatic adverse effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, and jaundice). Peliosis hepatis can be a life-threatening or fatal complication. Long-term therapy with intramuscular testosterone enanthate has produced multiple hepatic adenomas. JATENZO is not known to cause these adverse effects. Nonetheless, patients should be instructed to report any signs or symptoms of hepatic dysfunction (e.g. jaundice). If these occur, promptly discontinue JATENZO while the cause is evaluated.

5.9 Edema

Androgens, including JATENZO, may promote retention of sodium and water. Edema, with or without congestive heart failure, may be a serious complication in patients with pre-existing cardiac, renal, or hepatic disease. In addition to discontinuation of the drug, diuretic therapy may be required.

5.10 Gynecomastia

Gynecomastia may develop and persist in patients being treated for hypogonadism.

5.11 Sleep Apnea

The treatment of hypogonadal men with testosterone may potentiate sleep apnea in some patients, especially those with risk factors such as obesity or chronic lung disease.

5.12 Lipid Changes

Changes in the serum lipid profile may require dose adjustment of lipid lowering drugs or discontinuation of testosterone therapy. Monitor the lipid profile periodically, particularly after starting testosterone therapy.

5.13 Hypercalcemia

Androgens, including JATENZO, should be used with caution in cancer patients at risk of hypercalcemia (and associated hypercalciuria). Monitor serum calcium concentrations regularly during treatment with JATENZO in these patients.

5.14 Decreased Thyroxine-binding Globulin

Androgens, including JATENZO, may decrease concentrations of thyroxin-binding globulin, resulting in decreased total T4 serum concentrations and increased resin uptake of T3 and T4. Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.

5.15 Risk of Depression and Suicide

Depression and suicidal ideation has been reported in patients treated with JATENZO in clinical trials. Advise patients and caregivers to seek medical attention for manifestations

of new onset or worsening depression, suicidal ideation or behavior, anxiety, or other mood changes [*see Adverse Events (6.1)*].

6 ADVERSE REACTIONS

6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of JATENZO was evaluated in a randomized, controlled clinical study with 166 patients treated with JATENZO twice daily with morning and evening meals for approximately 4 months. All patients were started on 237 mg twice daily, then the dose was titrated to 158 mg, 198 mg, 316 mg, or 396 mg twice daily to achieve testosterone concentrations in the eugonadal range.

Table 2 summarizes adverse reactions (\geq 2%) reported in this 4-month study.

Table 2: Number (%) of Patients with Adverse Reactions ≥ 2% in a 4-Month Study with JATENZO

	Overall (N = 166)
Preferred Term	n (%)
Headache	8 (4.8)
Hematocrit increased	8 (4.8)
Hypertension	6 (3.6)
High-density lipoprotein decreased	5 (3.0)
Nausea	4 (2.4)

Among the 569 patients who received JATENZO in all Phase 2 and 3 trials combined, the following adverse reactions were reported in >2% of patients: polycythemia, diarrhea, dyspepsia, eructation, peripheral edema, nausea, increased hematocrit, headache, prostatomegaly, and hypertension.

Three of the 166 patients (1.8%) in the 4-month study experienced adverse reactions that led to premature discontinuation from the study, including rash (n=1) and headache (n=2).

BP Increases

In the 4-month clinical study, 24-hour ABPM was conducted on 166 patients. ABPM was conducted at baseline and at Day 139 of JATENZO therapy. A total of 135 patients had acceptable ABPM recordings at both time periods and were at least 85% compliant with study drug. In that group, the mean change in 24-hour systolic BP and diastolic BP from baseline to final on-treatment visit on Day 139 (n=135) was +4.9 mmHg (95% CI 3.5, 6.4) and +2.5 mmHg (95% CI 1.5, 3.6), respectively.

In patients with a history of hypertension who were receiving antihypertensive therapy, the mean ABPM systolic and diastolic BP increased by 5.4 mmHg [95% CI 3.3, 7.6] and 3.2 mmHg [95% CI 1.7, 4.7], respectively [n=67]. In patients with no history of hypertension, the mean ABPM systolic and diastolic blood pressure increased by 4.4 mmHg [95% CI 2.3, 6.4] and 1.8 mmHg [95% CI 0.2, 3.3], respectively [n=63].

Twelve (7.2%) patients on JATENZO either started antihypertensive medications or had their antihypertensive regimen increased during the study.

A total of 6 patients were reported to have an adverse reaction of hypertension (2 patients with hypertension and 4 patients with worsening hypertension), and 3 were reported to have an adverse reaction of increased blood pressure.

HR Increases

JATENZO increased mean heart rate by an average of 2.2 beats per minute (bpm) [95% CI (1.0, 3.3), N=135] during the study. Patients without a history of hypertension had a

greater average increase in mean heart rate (2.7 bpm [95% CI (0.8, 4.6), N=63]) compared to patients with treated hypertension (1.9 bpm [95% CI (0.3, 3.5), N=67)]).

Increases in Hematocrit

Increases in hematocrit were reported in 8 of the 166 (4.8%) patients, which occurred in the second half of the study. None of these increases led to premature discontinuation of JATENZO.

Headaches

Headaches were reported in 8 of the 166 patients (4.8%) of which three required treatment with analgesics or non-steroidal anti-inflammatory drugs and 2 led to premature discontinuation from the study. Five of these 8 patients had headache events that resolved within 1 to 2 days.

Depression and suicidal ideation

Two of the 166 patients (1.2%) reported either worsening depression (n=1) or newonset depression (n=1). One of the 569 patients (0.2%) in clinical trials had suicidal ideation. Each patient completed the study.

Increases in Serum PSA

The mean increase from baseline in PSA was 0.2 ng/mL (n=161). Increases in serum PSA concentrations, defined as an increase from baseline of at least 1.4 ng/mL or PSA greater than 4 ng/mL, occurred in 3 (1.9%) of the patients at the final visit.

Cardiovascular Outcomes

TRAVERSE was a randomized, double-blind, cardiovascular outcomes study to assess the cardiovascular (CV) safety of topical testosterone gel compared to placebo in 5198 hypogonadal men aged 45 to 80 years with a history of CV disease or with multiple CV risk factors. The primary outcome was the incidence of the composite endpoint of major adverse cardiovascular events (MACE), consisting of CV death, non-fatal myocardial infarction (MI), and non-fatal stroke.

The mean duration of therapy was approximately 22 months. The mean duration of follow-up was 33 months. Approximately 61% of all patients discontinued topical testosterone gel or placebo therapy.

The mean patient age (±SD) was 63.3 (7.9) years. Approximately 80% of patients were White, 17% were Black, and 3% were of other races or ethnic groups. Approximately 69%, 84%, and 93% had diabetes mellitus, hyperlipidemia, and hypertension, respectively. Approximately 55% had preexisting cardiovascular disease.

The mean serum testosterone concentration at baseline in patients receiving topical testosterone gel was 220.4 ng/dL (n=2129). The mean serum testosterone concentrations at 12 months, 24 months, 36 months, and 48 months in patients receiving topical testosterone gel were 440.5 ng/dL (n=1683), 420.9 ng/dl (n=1125), 428.7 ng/dL (n=731), and 365.2 ng/dL (n=220), respectively.

For patients treated with topical testosterone gel, the incidence of MACE was 7.0% (n=182 events) and for those receiving placebo, the incidence of MACE was 7.3% (n=190 events). The study demonstrated non-inferiority of topical testosterone gel versus placebo because the upper bound of 95% CI was less than the pre-specified risk margin, of 1.5 for MACE (Hazard Ratio 0.96 [95% CI: 0.78, 1.17]).

Additional Adverse Reactions Reported in TRAVERSE

Additional adverse reactions reported in TRAVERSE at an incidence rate >2% in either treatment group and greater in topical testosterone gel versus placebo included: nonfatal arrythmias warranting intervention (5.2% vs 3.3%), atrial fibrillation (3.5% vs 2.4%), acute kidney injury (2.3% vs 1.5%) and bone fracture (3.5% vs 2.5%). For the adverse reaction of bone fracture, each event was adjudicated by clinical review.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of testosterone. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Cardiovascular Disorders: myocardial infarction, stroke [*see Warnings and Precautions (5.4*), *Clinical Trial Experience (6.1*)]

Vascular Disorders: Venous thromboembolism [see Warnings and Precautions (5.1)]

7 DRUG INTERACTIONS

7.1 Insulin

Changes in insulin sensitivity or glycemic control may occur in patients treated with androgens. In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of anti-diabetic medication.

7.2 Oral Vitamin K Antagonist Anticoagulants

Changes in anticoagulant activity may be seen with androgens; therefore, more frequent monitoring of international normalized ratio (INR) and prothrombin time are recommended in patients taking warfarin, especially at the initiation and termination of androgen therapy.

7.3 Corticosteroids

The concurrent use of testosterone with corticosteroids may result in increased fluid retention and requires careful monitoring particularly in patients with cardiac, renal or hepatic disease.

7.4 Medications that May Also Increase Blood Pressure

Some prescription medications and nonprescription analgesic and cold medications contain drugs known to increase blood pressure. Concomitant administration of these medications with JATENZO may lead to additional increases in blood pressure [see Warnings and Precautions (5.4)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

JATENZO is contraindicated in pregnant women. Testosterone is teratogenic and may cause fetal harm based on data from animal studies and its mechanism of action [see *Contraindications (4) and Clinical Pharmacology (12.1)*]. Exposure of a female fetus to androgens may result in varying degrees of virilization. In animal developmental studies, exposure to testosterone in utero resulted in hormonal and behavioral changes in offspring and structural impairments of reproductive tissues in female and male offspring. These studies did not meet current standards for nonclinical development toxicity studies.

<u>Data</u>

Animal Data

In developmental studies conducted in rats, rabbits, pigs, sheep and rhesus monkeys, pregnant animals received intramuscular injection of testosterone during the period of organogenesis. Testosterone treatment at doses that were comparable to those used for testosterone replacement therapy resulted in structural impairments in both female

and male offspring. Structural impairments observed in females included increased anogenital distance, phallus development, empty scrotum, no external vagina, intrauterine growth retardation, reduced ovarian reserve, and increased ovarian follicular recruitment. Structural impairments seen in male offspring included increased testicular weight, larger seminal tubular lumen diameter, and higher frequency of occluded tubule lumen. Increased pituitary weight was seen in both sexes.

Testosterone exposure in utero also resulted in hormonal and behavioral changes in offspring. Hypertension was observed in pregnant female rats and their offspring exposed to doses approximately twice those used for testosterone replacement therapy.

8.2 Lactation

Risk Summary

JATENZO is not indicated for use in women.

8.3 Females and Males of Reproductive Potential

Infertility

During treatment with large doses of exogenous androgens, including JATENZO, spermatogenesis may be suppressed through feedback inhibition of the hypothalamicpituitary-testicular axis [see Warnings and Precautions (5.7)], possibly leading to adverse effects on semen parameters including sperm count. Reduced fertility is observed in some men taking testosterone replacement therapy. Testicular atrophy, subfertility, and infertility have also been reported in men who abuse anabolic androgenic steroids [see Drug Abuse and Dependence (9.2)]. With either type of use, the impact on fertility may be irreversible.

8.4 Pediatric Use

The safety and efficacy of JATENZO in pediatric patients less than 18 years old have not been established. Improper use may result in acceleration of bone age and premature closure of epiphyses.

8.5 Geriatric Use

There have not been sufficient numbers of geriatric patients involved in controlled clinical studies utilizing JATENZO to determine whether efficacy or safety in those over 65 years of age differs from younger subjects. No patients over 65 years of age were enrolled in the 4-month efficacy and safety clinical study utilizing JATENZO. Additionally, there is insufficient long-term safety data in geriatric patients utilizing JATENZO to assess the potentially increased risk of cardiovascular disease and prostate cancer.

Geriatric patients treated with androgens may also be at risk for worsening of signs and symptoms of BPH [see Warnings and Precautions (5.3)].

9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

JATENZO contains testosterone undecanoate, which is a Schedule III controlled substance as defined under the Controlled Substances Act.

9.2 Abuse

Drug abuse is intentional non-therapeutic use of a drug, even once, for its rewarding psychological and physiological effects. Abuse and misuse of testosterone are seen in male and female adults and adolescents. Testosterone, often in combination with other anabolic androgenic steroids (AAS), and not obtained by prescription through a pharmacy, may be abused by athletes and bodybuilders. There have been reports of misuse by men taking higher doses of legally obtained testosterone than prescribed and continuing testosterone despite adverse events or against medical advice.

Abuse-Related Adverse Reactions

Serious adverse reactions have been reported in individuals who abuse anabolic androgenic steroids and include cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and serious psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility and aggression.

The following adverse reactions have also been reported in men: transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemias, testicular atrophy, subfertility, and infertility.

The following additional adverse reactions have been reported in women: hirsutism, virilization, deepening of voice, clitoral enlargement, breast atrophy, male-pattern baldness, and menstrual irregularities.

The following adverse reactions have been reported in male and female adolescents: premature closure of bony epiphyses with termination of growth, and precocious puberty.

Because these reactions are reported voluntarily from a population of uncertain size and may include abuse of other agents, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

9.3 Dependence

Behaviors Associated with Addiction

Continued abuse of testosterone and other anabolic steroids, leading to addiction is characterized by the following behaviors:

- Taking greater dosages than prescribed
- Continued drug use despite medical and social problems due to drug use
- Spending significant time to obtain the drug when supplies of the drug are interrupted
- Giving a higher priority to drug use than other obligations
- Having difficulty in discontinuing the drug despite desires and attempts to do so
- Experiencing withdrawal symptoms upon abrupt discontinuation of use

Physical dependence is characterized by withdrawal symptoms after abrupt drug discontinuation or a significant dose reduction of a drug. Individuals taking supratherapeutic doses of testosterone may experience withdrawal symptoms lasting for weeks or months which include depressed mood, major depression, fatigue, craving, restlessness, irritability, anorexia, insomnia, decreased libido and hypogonadotropic hypogonadism.

Drug dependence in individuals using approved doses of testosterone for approved indications has not been documented.

10 OVERDOSAGE

There is a single report of acute overdosage with use of an approved injectable testosterone product: this subject had serum testosterone concentrations of up to 11,400 ng/dL which were implicated in a cerebrovascular accident.

One case of overdose with JATENZO was reported in clinical trials. This patient inadvertently took a higher dose than prescribed (474 mg twice daily, which is 20% higher than the maximum recommended dose). He did not report any adverse reactions associated with the overdose.


Treatment of overdosage consists of discontinuation of JATENZO and appropriate symptomatic and supportive care.

11 DESCRIPTION

JATENZO (testosterone undecanoate) for oral use is provided as a gelatin capsule containing testosterone undecanoate, a fatty-acid ester of testosterone. Testosterone undecanoate is a white to off-white yellow crystalline powder. Testosterone, an androgen, is formed by cleavage of the ester side chain of testosterone undecanoate.

Testosterone undecanoate is chemically described as 17β -hydroxyandrost-4-en-3-one undecanoate. It has the empirical formula of $C_{30}H_{48}O_3$ and the molecular weight of 456.7. The structural formula for testosterone undecanoate is presented in Figure 1.

Figure 1: Testosterone Undecanoate



JATENZO capsules are available in three strengths of 158 mg, 198 mg, and 237 mg.

The 158 mg strength is an opaque red capsule that contains 158 mg of testosterone undecanoate and is imprinted with "158" in white ink. The 198 mg strength is an opaque white capsule that contains 198 mg of testosterone undecanoate and is imprinted with "198" in red ink. The 237 mg strength is an opaque orange capsule that contains 237 mg of testosterone undecanoate and is imprinted with "237" in white ink. All capsule strengths also contain oleic acid, polyoxyl 40 hydrogenated castor oil (Cremophor RH 40), borage seed oil, peppermint oil, and butylated hydroxytoluene as inactive ingredients.

Gelatin capsule shells are composed of the following inactive ingredients: Gelatin, sorbitol, glycerin, purified water, iron oxide red, FD&C Yellow #6, and titanium dioxide.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Endogenous androgens, including testosterone and dihydrotestosterone (DHT), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal vesicles, penis and scrotum; the development of male hair distribution, such as facial, pubic, chest and axillary hair; laryngeal enlargement, vocal cord thickening, alterations in body musculature and fat distribution.

Male hypogonadism, a clinical syndrome resulting from insufficient secretion of testosterone, has two main etiologies. Primary hypogonadism is caused by defects of the gonads, such as Klinefelter syndrome or Leydig cell aplasia, whereas secondary hypogonadism (also known as hypogonadotropic hypogonadism) is the failure of the hypothalamus (or pituitary) to produce sufficient gonadotropins (FSH, LH).

12.2 Pharmacodynamics

No specific pharmacodynamic studies were conducted using JATENZO.

12.3 Pharmacokinetics

Absorption

JATENZO delivers physiologic amounts of testosterone, producing testosterone concentrations that approximate normal concentrations seen in healthy men.

JATENZO was taken orally at a starting dose of 237 mg twice per day with meals in a multicenter, open-label, randomized, 2-arm, active-controlled trial in hypogonadal males. The dose was adjusted, as needed, on Days 14 and 56 between a minimum of 158 mg twice per day and a maximum of 396 mg twice per day based on the average plasma testosterone concentration obtained over 24 hours after the morning dose. The average daily NaF-EDTA plasma testosterone concentration was $403 (\pm 128)$ ng/dL at the end of treatment, where the normal eugonadal range in NaF-EDTA plasma was 252-907 ng/dL in this study. Note that the titration scheme for use in clinical practice is based on serum total testosterone [*see Dosage and Administration (2.2)*].

Table 3 summarizes the pharmacokinetic (PK) parameters for plasma total testosterone in patients completing at least 105 days of JATENZO treatment administered twice daily.


PK Parameter		All Doses (N=151)
C _{avg} (ng/dL)	Mean	403
	SD	128
C _{max} (ng/dL)	Mean	1008
	SD	581

Table 3: NaF-EDTA Plasma Testosterone Cavg and Cmax at Final PK Visit

 $PK = pharmacokinetic; C_{avg} = 24$ -hour average concentration; $C_{max} = maximum$ concentration

Figure 2 summarizes the mean plasma total testosterone profile for the patients at the final PK visit.





When JATENZO was dosed with different breakfasts containing various amounts of fat, the bioavailability with the 30 g fat, 45 g fat, and high-calorie high-fat breakfasts was comparable, but there was a food effect with the 15 g fat breakfast compared to the 30 g fat breakfast. The 15 g fat breakfast had a 25% decrease in testosterone exposure compared to the 30 g fat breakfast.

Distribution

Circulating testosterone is primarily bound in serum to sex hormone-binding globulin (SHBG) and albumin. Approximately 40% of testosterone in plasma is bound to SHBG, 2% remains unbound (free) and the rest is loosely bound to albumin and other proteins.

<u>Metabolism</u>

The androgenic activity of testosterone undecanoate occurs after the ester bond linking the testosterone to the undecanoic acid is cleaved by endogenous non-specific esterases. Undecanoic acid is metabolized like all fatty acids via the beta-oxidation

pathway.

Testosterone is metabolized to various 17-keto steroids through two different pathways. The major active metabolites of testosterone are dihydrotestosterone (DHT) and estradiol.

Excretion

About 90% of a dose of testosterone given intramuscularly is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites. About 6% of a dose is excreted in the feces, mostly in the unconjugated form. Inactivation of testosterone occurs primarily in the liver.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Testosterone has been tested by subcutaneous injection and implantation in mice and rats. In mice, the implant induced cervical-uterine tumors, which metastasized in some cases. There is suggestive evidence that injection of testosterone into some strains of female mice increases their susceptibility to hepatoma. Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver in rats.

<u>Mutagenesis</u>

Testosterone was negative in the *in vitro* Ames and in the *in vivo* mouse micronucleus assays.

Impairment of Fertility

The administration of exogenous testosterone suppresses spermatogenesis in the rat, dog and non-human primates, which was reversible on cessation of the treatment.

13.2 Animal Toxicology and/or Pharmacology

JATENZO has been evaluated in 3- and 9-month repeat-dose oral toxicity studies in male eugonadal dogs. JATENZO caused exaggerated pharmacological effects on androgenresponsive tissues including testes, epididymis, prostate and adrenals at exposures to testosterone or testosterone undecanoate, comparable to the maximum human exposure based on AUC comparisons. Following a 4-week drug-free period, a reduced severity of these findings was observed, suggesting partial reversibility.

In adrenal glands, moderate to severe atrophy, characterized as thinning of the zona fasciculata, was observed with reduced adrenal weights and reduced circulating levels of cortisol in testosterone undecanoate-treated dogs after 3 months of treatment. Following 9-month treatment, there were dose-related decreases in adrenal weights in testosterone undecanoate-treated male dogs and moderate adrenal vacuolation in one testosterone undecanoate-treated male dog. The clinical significance of these adrenal and cortisol findings is unknown.

14 CLINICAL STUDIES

14.1 Clinical Trials in Hypogonadal Males

The efficacy and safety of JATENZO was evaluated in 166 adult hypogonadal males in an open-label study of approximately 4 months duration (NCT02722278). The study included a Screening Phase, a Treatment Titration Phase, and a Treatment Maintenance Phase.

JATENZO was taken orally at a starting dose of 237 mg twice per day with meals. The

dose was adjusted on Days 21 and 56 between a minimum of 158 mg twice per day and a maximum of 396 mg twice per day on the basis of the average testosterone concentration obtained over 24 hours post-morning dose.

The primary endpoint was the percentage of patients with mean plasma total testosterone concentration (C_{avg}) over 24-hours within the normal eugonadal range on the final PK visit of the study.

Secondary endpoints were the percentage of patients with a maximum total testosterone concentration (C_{max}) above three predetermined limits: less than or equal to 1500 ng/dL, between 1800 and 2500 ng/dL, and greater than 2500 ng/dL.

One hundred and forty-five (87%) of the 166 hypogonadal men who received JATENZO had a mean total testosterone concentration (C_{avg}) within the normal eugonadal range at the end of treatment.

The percentage of patients who received JATENZO and had C_{max} less than or equal to 1500 ng/dL, between 1800 and 2500 ng/dL, and greater than 2500 ng/dL at the final PK visit were 83%, 3%, and 3%, respectively. Note that the testosterone concentrations were not measured in serum but the effects of different sample preparation conditions were accounted for in data analysis of the results shown here. The titration scheme for use in clinical practice is based on serum total testosterone [see Dosage and Administration (2.2)].

16 HOW SUPPLIED/STORAGE AND HANDLING

JATENZO (testosterone undecanoate) capsules are available in three strengths of 158 mg, 198 mg, and 237 mg. Capsules are packaged as 120 units in wide-mouth, round, white HDPE bottles with white, polypropylene, child resistant caps and induction-sealed liner.

158 mg capsules are opaque red capsules imprinted with "158" in white ink and are supplied in bottles: NDC 69087-158-12.

198 mg capsules are opaque white capsules imprinted with "198" in red ink and are supplied in bottles: NDC 69087-198-12.

237 mg capsules are opaque orange capsules imprinted with "237" in white ink and are supplied in bottles: NDC 69087-237-12.

Keep JATENZO out of reach of children.

Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Avoid exposing the capsules to moisture (store in a dry place).

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Venous Thromboembolism

• Inform patients that JATENZO can cause venous thromboembolism. Advise patients of the signs and symptoms of venous thromboembolism, which may include the following: lower limb pain, edema, or erythema; and dyspnea or chest pain. Advise patients to promptly report the signs and symptoms of venous thromboembolism, discontinue use of JATENZO, and seek urgent medical care.

Increased Blood Pressure

- Inform patients that JATENZO can increase BP which can increase cardiovascular risk over time.
- Instruct patients about the importance of monitoring BP periodically while on JATENZO. If BP increases while on JATENZO, antihypertensive medications may need to be started, added, or adjusted to control BP, or JATENZO may need to be discontinued.

Other Adverse Reactions

Inform patients that treatment with androgens may lead to adverse reactions which include:

- Changes in urinary habits related to effects on prostate size, such as increased urination at night, hesitancy, frequency, urinary urgency, having a urine accident, being unable to pass urine and weak urine flow
- Breathing disturbances that may reflect obstructive sleep apnea, including those associated with sleep, or excessive daytime sleepiness
- Too frequent or persistent erections of the penis
- Ankle swelling that may reflect peripheral edema
- Red blood cell count increase
- PSA increase
- Nausea and vomiting

Instruct patients to report any changes in their state of health, such as changes in urinary habits, breathing, sleep, and mood including new onset or worsening of depression, or suicidal ideation.

Keep JATENZO out of the reach of children.

Distributed by: Tolmar, Inc. Fort Collins, CO 80526

131924 Rev. 1 03/2025

MEDICATION GUIDE JATENZO[®] (juh-TEN-zoh) (testosterone undecanoate) capsules, for oral use CIII

What is JATENZO?

JATENZO is a prescription medicine that contains testosterone. JATENZO is used to treat adult men who have low or no testosterone due to certain medical conditions. It is not known if JATENZO is safe or effective to treat men who have low testosterone due to aging.

It is not known if JATENZO is safe or effective in children younger than 18 years old. Improper use of JATENZO may affect bone growth in children.

JATENZO is a controlled substance (CIII) because it contains testosterone that can be a target for people who abuse prescription medicines. Keep your JATENZO in a safe place to protect it. Never give your JATENZO to anyone else, even if they have the same symptoms you have. Selling or giving away this medicine may harm others and is against the law.

JATENZO is not meant for use by women.

Do not take JATENZO if you:

- have breast cancer.
- have or might have prostate cancer.
- are a woman who is pregnant. JATENZO may harm your unborn baby.
- are allergic to JATENZO or any ingredients in JATENZO. See the end of this Medication Guide for a complete list of ingredients in JATENZO.

Before you take JATENZO, tell your healthcare provider about all of your medical conditions, including if you:

- have high blood pressure or are treated for high blood pressure.
- have heart problems.
- have high red blood cell count (hematocrit) or high hemoglobin laboratory value.
- have urinary problems due to an enlarged prostate.
- have liver or kidney problems.
- have a history of mental health illness including suicidal thoughts or actions, depression, anxiety or mood disorder.
- have problems breathing while you sleep (sleep apnea).

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Using JATENZO with certain other medicines can affect each other. Especially, tell your healthcare provider if you take:

- insulin
- medicines that decrease blood clotting (blood thinners)
- corticosteroids.
- medicines that increase blood pressure such as some cold medicines and pain medicines.

Know the medicines you take. Ask your healthcare provider or pharmacist for a list of these medicines, if you are not sure. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.

How should I take JATENZO?

- Take JATENZO exactly as your healthcare provider tells you take it.
- Take JATENZO by mouth two times daily. Take 1 time in the morning and take 1 time in the evening.
- Take JATENZO with food.
- Your healthcare provider may change your JATENZO dose. Do not change your JATENZO dose without talking to your healthcare provider.

What are the possible side effects of JATENZO? JATENZO may cause serious side effects including:

- Increase in blood pressure.
 - JATENZO can increase your blood pressure, which can increase your risk of having a heart attack or stroke over time. Your risk may be greater if you already have heart disease or if you have had a heart attack or stroke.
 - You may need to start new blood pressure medicines or have your medicines adjusted to control your blood pressure while on JATENZO.
 - If your blood pressure cannot be controlled, JATENZO may need to be stopped.
 - Your healthcare provider should check your blood pressure while you use JATENZO.
- Increase in red blood cell count (hematocrit) or hemoglobin.
 - JATENZO increases red blood cell counts in some patients. High red blood cell counts increase the risk of blood clots, strokes, and heart attacks.
 - $\circ~$ You may need to stop JATENZO if your red blood cell count increases.
 - Your healthcare provider should check your red blood cell count and hemoglobin while you use JATENZO.
- If you already have an enlarged prostate, your signs and symptoms may worsen while using JATENZO.

These may include:

- increased urination at night
- trouble starting your urine stream
- urinating many times during the day
- urge to go to the bathroom right away
- a urine accident
- inability to pass urine or weak urine flow
- **Increased risk of prostate cancer**. Your healthcare provider should check you for prostate cancer or any other prostate problems before you start and while you use JATENZO.
- **Blood clots in the legs or lungs**. Signs and symptoms of a blood clot in your leg can include pain, swelling or redness. Signs and symptoms of a blood clot in your lungs can include difficulty breathing or chest pain.
- **Abuse**. Testosterone can be abused, when taken at higher than prescribed doses and when used with other anabolic androgenic steroids. Abuse can cause serious heart and psychological side effects. Your healthcare provider should check you for signs of abuse before and during treatment with JATENZO.
- In large doses JATENZO may lower your sperm count.

• Liver problems. Symptoms of liver problems may include:

- nausea or vomiting
- vellowing of your skin or whites of your eyes
- dark urine
- pain on the right side of your stomach area (abdominal pain)
- Swelling of your ankles, feet, or body (edema), with or without heart failure.
- Enlarged or painful breasts.
- Breathing problems while you sleep (sleep apnea).
- Changes in mood. Talk to your healthcare provider if you have changes in mood or behavior including, new or worsening depression, or suicidal thoughts.

Call your healthcare provider right away if you have any of the serious side effects listed above.

The most common side effects of JATENZO include:

- increased red blood cell count
 burping

• diarrhea • heart burn

- foot, leg and ankle swelling
- nausea
- enlarged prostate gland
- high blood pressure
 - headache

Other side effects include more erections than are normal for you or erections that last a long time.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of JATENZO. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store JATENZO?

- Store JATENZO at room temperature between 68°F to 77°F (20°C to 25°C).
- Store JATENZO in a dry place.

Keep JATENZO and all medicines out of the reach of children. General information about the safe and effective use of JATENZO

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use IATENZO for a condition for which it was not prescribed. Do not give JATENZO to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about JATENZO that is written for health professionals.

What are the ingredients in JATENZO?

Active ingredient: testosterone undecanoate

Inactive ingredients: oleic acid, polyoxyl 40 hydrogenated castor oil (Cremophor RH 40), borage seed oil, peppermint oil, and butylated hydroxytoluene. The ingredients of the soft gelatin capsule shells are gelatin, sorbitol, glycerin, purified water, iron oxide red, FD&C Yellow #6, and titanium dioxide.

Distributed by: Tolmar, Inc. Fort Collins, CO 80526

For more information, go to www.JATENZO.com or call 1-844-4TO-LMAR.

This Medication Guide has been approved by the U.S. Food and Issued: 03/2025 Drug Administration

PRINCIPAL DISPLAY PANEL

158 mg Bottle Label



198 mg Bottle Label



237 mg Bottle Label



JATENZO testosterone undecanoate capsule, liquid filled Product Information Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:69087-158

	nistration	ORAL	DEA	Schedule	CIII	
Active Ingred	lient/Active	e Moiety				
	-	edient Name			of Strength	Strengt
TESTOSTERONE JNII:3XMK78S47O)		E (UNII: H16A5VCT9C) (T	ESTOSTERON	E - TESTOSTE UNDECANO		158 mg
nactive Ingr	odionto					
nactive ingr	ealents	Ingredient Na	me		S	trength
DLEIC ACID (UNII:	2UMI9U37CP)					
OLYOXYL 40 HY	DROGENATED	CASTOR OIL (UNII: 7YO	C686GQ8F)			
BORAGE OIL (UNI	I: F8XAG1755S)				
PEPPERMINT OIL	UNII: AV092KU	J4JH)				
UTYLATED HYD	ROXYTOLUEN	E (UNII: 1P9D0Z171K)				
GELATIN (UNII: 2G	86QN327L)					
SORBITOL (UNII: 5						
GLYCERIN (UNII: P						
WATER (UNII: 059) FERRIC OXIDE RE		3(675)				
FERRIC OXIDE RE	•	,				
FITANIUM DIOXIC	•	· ·				
		_ , ,				
Product Char	actoristics					
Color			Scor			
Shape		(opaque)) (CAPSULE)	Size		no sc 21mn	
Flavor	CAISOLL			int Code	158	1
Contains			mpi	int code	150	
Packaging						
	F	ackage Descriptio	n	Marketing St Date		eting End Date
# Item Code	F 12 in 1 BOX	ackage Descriptio	n			
NDC:69087-	12 in 1 BOX	LE, PLASTIC; Type 0: No		Date		
 # Item Code NDC:69087- 158-12 	12 in 1 BOX 120 in 1 BOTT	LE, PLASTIC; Type 0: No		Date		
 # Item Code 1 NDC:69087- 158-12 1 	12 in 1 BOX 120 in 1 BOT Combination I	LE, PLASTIC; Type 0: No Product		Date		
 # Item Code 1 NDC:69087- 158-12 1 	12 in 1 BOX 120 in 1 BOT Combination I	LE, PLASTIC; Type 0: No Product	t a	Date	art Marke	
 # Item Code NDC:69087- 158-12 Marketing Category 	12 in 1 BOX 120 in 1 BOT Combination I	TLE, PLASTIC; Type 0: No Product tion ation Number or Mo Citation	t a	Date 08/01/2019 Marketing Sta	art Marke	Date eting End
 # Item Code 1 NDC:69087- 158-12 1 Marketing Category 	12 in 1 BOX 120 in 1 BOT Combination I Informa Applic	TLE, PLASTIC; Type 0: No Product tion ation Number or Mo Citation	t a	Date 08/01/2019 Marketing Sta Date	art Marke	Date eting End
<pre># Item Code 1 NDC:69087- 158-12 1 Marketing Category NDA</pre>	12 in 1 BOX 120 in 1 BOT Combination I Informa Applic	TLE, PLASTIC; Type 0: No Product tion ation Number or Mo Citation	t a	Date 08/01/2019 Marketing Sta Date	art Marke	Date eting End
<pre># Item Code NDC:69087- 158-12 Marketing Marketing Category NDA ATENZO</pre>	12 in 1 BOX 120 in 1 BOT Combination I Informa Applic NDA20608	TLE, PLASTIC; Type 0: No Product tion ation Number or Mo Citation 9	t a	Date 08/01/2019 Marketing Sta Date	art Marke	Date eting End
<pre># Item Code 1 NDC:69087- 158-12 1 Marketing Category NDA ATENZO</pre>	12 in 1 BOX 120 in 1 BOT Combination I Informa Applic NDA20608	TLE, PLASTIC; Type 0: No Product tion ation Number or Mo Citation	t a	Date 08/01/2019 Marketing Sta Date	art Marke	Date eting End
<pre># Item Code 1 NDC:69087- 158-12 1 Marketing Marketing Category NDA ATENZO</pre>	12 in 1 BOX 120 in 1 BOT Combination I Informa Applic NDA20608	TLE, PLASTIC; Type 0: No Product tion ation Number or Mo Citation 9	t a	Date 08/01/2019 Marketing Sta Date	art Marke	Date eting End
<pre># Item Code 1 NDC:69087- 158-12 1 Marketing Category NDA ATENZO estosterone ur</pre>	12 in 1 BOX 120 in 1 BOT Combination I Informa Applic NDA20608	TLE, PLASTIC; Type 0: No Product tion ation Number or Mo Citation 9	t a nograph	Date 08/01/2019 Marketing Sta Date	art Marke	eting End Date
<pre># Item Code I NDC:69087- 158-12 I Marketing Category NDA ATENZO estosterone ur Product Info</pre>	12 in 1 BOX 120 in 1 BOTT Combination I Informa Applic NDA20608 ndecanoate of rmation	LE, PLASTIC; Type 0: No Product tion ation Number or Mo Citation 9	ta nograph	Date 08/01/2019 Marketing Sta Date 08/01/2019	art Marke	eting End Date
 # Item Code NDC:69087- 158-12 Marketing Category Marketing Category	12 in 1 BOX 120 in 1 BOTT Combination I Informa Applic NDA20608 ndecanoate of rmation	TLE, PLASTIC; Type 0: No Product tion ation Number or Mo Citation 9 capsule, liquid filled HUMAN PRESCRIPTION	ta nograph	Date 08/01/2019 Marketing Sta Date 08/01/2019	art Marke	eting End Date

 Active Ingredient/Active Moiety

 Ingredient Name
 Basis of Strength
 Strength

 TESTOSTERONE UNDECANOATE (UNII: H16A5VCT9C) (TESTOSTERONE -UNII: 3XMK785470)
 TESTOSTERONE UNDECANOATE
 198 mg

Ingredient Name Strength OLEIC ACID (UNII: 2UMI9U37CP) Strength OLEIC ACID (UNII: 2UMI9U37C55) Strength Strength Strength BORAGE OIL (UNII: 2E080C0827L) Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength Strength <th colspan="2" s<="" th=""></th>		
Ingredient Name Strength OLEIC ACID (UNII: 201490137CP) Strength POLYOXYL 40 HYDROGENATED CASTOR OIL (UNII: 7YC6865Q8F) BORAEE OIL (UNII: F8XAG17555) PEPPERMINT OIL (UNII: 6X8AG17555) Strength PEPPERMINT OIL (UNII: 70032K04)H) SUTURE (UNII: 70032K04)H) BUTYLATED HYDROXYTOLUENE (UNII: 19902171K) SORBITOL (UNII: 700680327L) SORBITOL (UNII: 2086Q0327L) SORBITOL (UNII: 2086Q0327L) SORBITOL (UNII: 505060AC300X) Imprint Code SUYCERIN (UNII: 5050607C0R) Imprint Code TITANIUM DIOXIDE (UNII: 15FIX9V2JP) Size Product Char-cteristics Size Coltains Imprint Code Packaging Imprint Code # tem Code Package Description Marketing Start Date 1 120 in 1 BOTTLE, PLASTIC; Type 0: Not a I 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Marketing Information Marketing Start Marketing Citation Number or Monograph Marketing Start NDA NDA206089 08/01/2019		
Ingredient Name Strength OLEIC ACID (UNII: 201490137CP) Strength POLYOXYL 40 HYDROGENATED CASTOR OIL (UNII: 7YC6865Q8F) BORAEE OIL (UNII: F8XAG17555) PEPPERMINT OIL (UNII: 6X8AG17555) Strength PEPPERMINT OIL (UNII: 70032K04)H) SUTURE (UNII: 70032K04)H) BUTYLATED HYDROXYTOLUENE (UNII: 19902171K) SORBITOL (UNII: 700680327L) SORBITOL (UNII: 2086Q0327L) SORBITOL (UNII: 2086Q0327L) SORBITOL (UNII: 505060AC300X) Imprint Code SUYCERIN (UNII: 5050607C0R) Imprint Code TITANIUM DIOXIDE (UNII: 15FIX9V2JP) Size Product Char-cteristics Size Coltains Imprint Code Packaging Imprint Code # tem Code Package Description Marketing Start Date 1 120 in 1 BOTTLE, PLASTIC; Type 0: Not a I 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Marketing Information Marketing Start Marketing Citation Number or Monograph Marketing Start NDA NDA206089 08/01/2019		
OLEIC ACID (UNII: 2UMI9U37CP) Image: Castor oil (UNII: 7YC686GQ8F) Image: Castor oil (UNII: 7YC686GQ8F) BORAGE OIL (UNII: FRAG175S) PEPPERVIII OIL (UNII: 7X092KU4JH) Image: Castor oil (UNII: 7P2686GQ8F) BUTYLATED HYDROXYTOLUENE (UNII: 1P9D02171K) Image: Castor oil (UNII: 508106425R) Image: Castor oil (UNII: 508106425R) GLYCERIN (UNII: 50860425R) Image: Castor oil (UNII: 517K9V2JP) Image: Castor oil (UNII: 517K9V2JP) Product Char: Store no score Shape CAPSULE (CAPSULE) Size 23mm Flavor Imprint Code 198 198 Contains Imprint Code 198 198 Olicition State (CapSULE) Size 23mm 1 No. NDA206089 08/01/2019 Imprint Code 198 Olicition Number or Monograph Marketing Start Marketing End Date NDA NDA206089 08/01/2019 Imprint Code 108		
POLYOXYL 40 HYDROGENATED CASTOR OIL (UNII: 7YC688609E) Image: Castor of Castor		
BORAGE OIL (UNII: F8XAG1755S) PEPPERMINT OIL (UNII: AV032KUJH) BUTYLATED HYDROXYTOLUENE (UNII: 1P9D02171K) GELATIN (UNII: 2G860337L) SORBITOL (UNII: 506760A25R) GLYCERIN (UNII: 506760A00R) TITANIUM DIOXIDE (UNII: 15FIX9V2JP) Product Characteristics Color white (white (opaque)) Score no score Shape CAPSULE (CAPSULE) Size 23mm Flavor 198 Contains 198 Package Description Marketing Start Date 198 Product Characteristics VIII (UNII: 2000) Product Characteristics VIII (UNII: 2000) Flavor 198 Package Description Marketing Start Date Marketing End Date 198 Product J 100C:69087- 12 in 1 BOX 08/01/2019 JUIC (UNII: 2000) 1 NDC:69087- 12 in 1 BOX 08/01/2019 JUIC (UNII: 2000) Product VIII BOTILE, PLASTIC; Type 0: Not a Combination Product VIII BOX 08/01/2019 JUIC (UNII: 2000) Product VIII BOTILE, PLASTIC; Type 0: Not a Combination Product VIII BOX 08/01/2019 JUIC (UNII: 2000) NDA NDA206089 08/01/2019 JUIC (UNII: 2000) TERSUB VIII BOTILE, PLASTIC; Type 0: Not a COMBINATION VIII STREED VIII SUBJECT VIII SCORED VIII SUBJECT VIIII SUBJECT VIIIIIII		
BUTYLATED HYDROXYTOLUENE (UNII: 199D02171K) GELATIN (UNII: 26860N327L) SORBITOL (UNII: 506T60A2SR) GUYCERIN (UNII: 506T60A2SR) GUYCENIN (UNII: 509QF0K00R) TITANIUM DIOXIDE (UNII: 15FIX9V2JP) Product Characteristics Color white (white (opaque)) Stape CAPSULE (CAPSULE) Size no score Shape CAPSULE (CAPSULE) Flavor 0 Contains 0 Packaging Packaging Warketing Start Marketing End Date 0 NDC:69087- 1 2 in 1 BOTTLE, PLASTIC; Type 0: Not a 1 NDC:69087- 1 2 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product Marketing Start Marketing End Date 0 Marketing Start Marketing End Marketing End Date 0 Marketing End Marketing End Marketing End Marketing Start Marketing End Marketing Start Marke		
GELATIN (UNII: 2G86QN327L) Image: Construct of the second se		
SORBITOL (UNII: 506760A25R) Indexing the second secon		
GLYCERIN (UNII: PDC6A3C00X) Image: State of the s		
WATER (UNII: 0590F0K00R) Intransitive division of the second division divisio divisio division division division division divisio d		
TITANIUM DIOXIDE (UNII: 15FIX9V2JP) Product Charsetristics Color white (white (opaque)) Score no score Shape CAPSULE (CAPSULE) Size 23mm Flavor 23mm Contains 198 Contains 198 Contains 198 Package Description 108/01/2019 1 Item Code Package Description 08/01/2019 1 NDC:69087- 12 In 1 BOX 08/01/2019 1 20 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 120 in 1 BOTTLE, PLASTIC; Type 0: Not a NDA NDA2060B9 08/01/2019 190 NDA NDA2060B9 190 NDA NDA N		
Product Characteristics color white (white (opaque)) Score no score Shape CAPSULE (CAPSULE) Size 23mm Flavor Imprint Code 198 V V V V V V Marketing Start Marketing Start Marketing End Date NDC OB/01/2019 V V V V V NDC V V V V V V V		
Color white (white (opaque)) Score no score Shape CAPSULE (CAPSULE) Size 23mm Flavor Imprint Code 198 Contains Marketing Start Marketing End Date NDC:69087- 198-12 12 in 1 BOX 08/01/2019 Marketing End Date NDC:69087- 198-12 12 in 1 BOX 08/01/2019 Understand Vertication Marketing Category Application Number or Monograph Citation Marketing Start Marketing End Date NDA NDA206089 08/01/2019 Understand Marketing End Date Date NDA206089 08/01/2019 Understand Understand Understand Understand NDA206089 08/01/2019 Understand Understand Understand Understand NDA206089 08/01/2019 Understand Understand		
Color white (white (opaque)) Score no score Shape CAPSULE (CAPSULE) Size 23mm Flavor Imprint Code 198 Contains Marketing Start Marketing End Date NDC:69087- 198-12 12 in 1 BOX 08/01/2019 08/01/2019 1 NDC:69087- 198-12 12 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 08/01/2019 Imprint Code Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA206089 08/01/2019 Imprint Code Imprint Code		
Color white (white (opaque)) Score no score Shape CAPSULE (CAPSULE) Size 23mm Flavor Imprint Code 198 Contains Marketing Start Marketing End Date NDC:69087- 198-12 12 in 1 BOX 08/01/2019 Marketing End Date NDC:69087- 198-12 12 in 1 BOX 08/01/2019 Understand Vertication Marketing Category Application Number or Monograph Citation Marketing Start Marketing End Date NDA NDA206089 08/01/2019 Understand Marketing End Date Date NDA206089 08/01/2019 Understand Understand Understand Understand NDA206089 08/01/2019 Understand Understand Understand Understand NDA206089 08/01/2019 Understand Understand		
Shape CAPSULE (CAPSULE) Size 23mm Flavor Imprint Code 198 Contains Imprint Code 198 Packaging Narketing Start Marketing End Date 1 NDC:69087- 198-12 12 in 1 BOX 08/01/2019 1 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 08/01/2019 Imprint Code Marketing End Date Marketing Start Marketing End Date Marketing Category NDA206089 08/01/2019 Marketing Start Marketing End Date Jate Marketing Category NDA206089 NDA NDA206089 08/01/2019 Imprint Code USULE (CAPSULE (Information		
Flavor Contains Imprint Code 198 Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:69087- 12 in 1 BOX 08/01/2019 08/01/2019 1 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 08/01/2019 Imprint Code Imprint Code Marketing Category Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA206089 08/01/2019 08/01/2019 Imprint Code Imprint Code		
Addition of the second of the		
Marketing Start Marketing End Date 1 NDC:69087- 12 in 1 BOX 08/01/2019 1 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 08/01/2019 Marketing Start Combination Product Marketing Start Combination Product Marketing Start Combination Product Marketing Start Combination Product Marketing Start Date Marketing Start Marketing End Date NDA NDA206089 08/01/2019 Marketing Start Date Marketing Start Date VIDA206089 NDA206089 OB/01/2019		
# Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:69087- 198-12 12 in 1 BOX 08/01/2019 08/01/2019 1 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 08/01/2019 1000000000000000000000000000000000000		
# Item Code Package Description Marketing Start Date Marketing End Date 1 NDC: 69087- 198-12 12 in 1 BOX 08/01/2019 08/01/2019 1 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 08/01/2019 1000000000000000000000000000000000000		
# Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:69087- 198-12 12 in 1 BOX 08/01/2019 08/01/2019 1 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 08/01/2019 1000000000000000000000000000000000000		
Itelin Code Package Description Date Date 1 NDC:69087- 198-12 12 in 1 BOX 08/01/2019 08/01/2019 1 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product 08/01/2019 08/01/2019 Marketing Information Marketing Start Application Number or Monograph Citation Marketing Start Date NDA NDA206089 08/01/2019 08/01/2019		
1 198-12 120 in 1 BOX 08/01/2019 1 120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product Image: Combination Product Marketing Information Application Number or Monograph Citation Marketing Start Date NDA NDA206089 08/01/2019		
I Combination Product Image: Combination Product Marketing Information Image: Citation Number or Monograph Citation Date Marketing Start Date Marketing Category NDA206089 08/01/2019 Marketing Start Date NDA NDA206089 08/01/2019 Image: Citation Product JATENZO Image: Category Product Information Image: Citation Product Pro		
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA206089 08/01/2019 08/01/2019 JATENZO testosterone undecanoate capsule, liquid filled		
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA206089 08/01/2019 08/01/2019 JATENZO testosterone undecanoate capsule, liquid filled		
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA206089 08/01/2019		
Category Citation Date Date NDA NDA206089 08/01/2019		
NDA NDA206089 08/01/2019 JATENZO testosterone undecanoate capsule, liquid filled Product Information		
Product Information		
Product Information		
Product Information		
Product Information		
Product Information		
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:69087-237		
Route of Administration ORAL DEA Schedule CIII		
Route of Administration ORAL DEA Schedule CIII		
Active Ingredient/Active Moiety		
Ingredient Name Basis of Strength Strength		
TESTOSTERONE LINDECANOATE (UNII) HIGASVCTQC) (TESTOSTERONE TESTOSTERONE		
UNII:3XMK78S470) UNDECANOATE (ONII: TIDASVETSE) (TESTOSTERONE - TESTOSTERONE - 237 mg		

Inactive Ingredients	
Ingredient Name	Strength
OLEIC ACID (UNII: 2UMI9U37CP)	
POLYOXYL 40 HYDROGENATED CASTOR OIL (UNII: 7YC686GQ8F)	
BORAGE OIL (UNII: F8XAG1755S)	
PEPPERMINT OIL (UNII: AV092KU4JH)	

	06T60A25R) 0C6A3C0OX) 0F0KO0R) 0. 6 (UNII: H77VEI93A8) E (UNII: 15FIX9V2JP)		
GLYCERIN (UNII: PE WATER (UNII: 059Q FD&C YELLOW NO TITANIUM DIOXIDI Product Chara Color	DC6A3C00X) DF0K00R) D. 6 (UNII: H77VEI93A8) E (UNII: 15FIX9V2JP) Acteristics		
WATER (UNII: 059Q FD&C YELLOW NO TITANIUM DIOXIDI Product Chara Color	b FOKOOR) b . 6 (UNII: H77VEI93A8) e (UNII: 15FIX9V2JP) acteristics		
FD&C YELLOW NO TITANIUM DIOXIDI Product Chara Color	D. 6 (UNII: H77VE193A8) E (UNII: 15FIX9V2JP)		
TITANIUM DIOXIDI Product Chara Color	e (UNII: 15FIX9V2JP)		
Product Chara ^{Color}	acteristics		
Color			
Color			
Shane	orange (orange (opaque))	Score	no score
Jiiape	CAPSULE (CAPSULE)	Size	26mm
Flavor		Imprint Code	237
Contains			
Packaging			
# Item Code	Package Description	Marketing Start Date	Marketing End Date
1 NDC:69087- 237-12	12 in 1 BOX	08/01/2019	
	120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product		
Markotica	Information		
•			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA206089	08/01/2019	
Marketing	120 in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product Information Application Number or Monograph	Marketing Start	

Labeler - TOLMAR Inc. (791156578)

Revised: 3/2025

TOLMAR Inc.